Raloxifene and alendronate containing thin mesoporous titanium oxide films improve implant fixation to bone

N. Harmankaya, J. Karlsson, A. Palmquist, M. Halvarsson, K. Igawa, M. Andersson, P. Tengvall

Research output: Contribution to journalArticlepeer-review

61 Citations (Scopus)


This study tested the hypothesis that osteoporosis drug-loaded mesoporous TiO2 implant coatings can be used to improve bone-implant integration. Two osteoporosis drugs, Alendronate (ALN) and Raloxifene (RLX), were immobilized in nanoporous oxide films prepared on Ti screws and evaluated in vivo in rat tibia. The drug release kinetics were monitored in vitro by quartz crystal microbalance with dissipation and showed sustained release of both drugs. The osteogenic response after 28 days of implantation was evaluated by quantitative polymerase chain reaction (qPCR), removal torque, histomorphometry and ultrastructural interface analysis. The drug-loaded implants showed significantly improved bone fixation. In the case of RLX, stronger bone-remodelling activity was observed compared with controls and ALN-loaded implants. The ultrastructural interface analysis revealed enhanced apatite formation inside the RLX coating and increased bone density outside the ALN coating. Thus, this novel combination of a thin mesoporous TiO2 carrier matrix and appropriate drugs can be used to accelerate implant fixation in trabecular bone.

Original languageEnglish
Pages (from-to)7064-7073
Number of pages10
JournalActa Biomaterialia
Issue number6
Publication statusPublished - Jun 2013
Externally publishedYes


  • Bisphosphonate
  • Drug delivery
  • Mesoporous
  • Raloxifene
  • Titanium

ASJC Scopus subject areas

  • Biotechnology
  • Biomaterials
  • Biochemistry
  • Biomedical Engineering
  • Molecular Biology


Dive into the research topics of 'Raloxifene and alendronate containing thin mesoporous titanium oxide films improve implant fixation to bone'. Together they form a unique fingerprint.

Cite this